ImmunoForge
Seoul · Founded 2017
About ImmunoForge
ImmunoForge is a developer of a new drug intended for treating sarcopenia and cancer. The company has a solution for sarcopenia based on its drug repurposing patents as well as a strong kinase inhibitor pipeline for genomically defined rare cancers, such as chronic myelogenous leukemia, enabling patients to get cured quickly.
Company Facts
- Founded: 2017
- Legal name: ImmunoForge, Co. Ltd
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $30.5M
- Funding stage: Late Stage Venture
- Last round: Series Unknown (Dec 2020)
- Website: immunoforge.com
- Phone: +82-70-7721-0755
Canonical: https://fsome.com/organization/immunoforge-8343264 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.